3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Epidermal growth factor receptor signalling regulates granulocyte-macrophage colony-stimulating factor production by airway epithelial cells and established allergic airway disease

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <div class="section"> <a class="named-anchor" id="S1"> <!-- named anchor --> </a> <h5 class="section-title" id="d8965602e156">Background</h5> <p id="P1">Airway epithelial cells (AEC) are increasingly recognized as a major signaling center in the pathogenesis of allergic asthma. A previous study demonstrated that epithelial growth factor receptor (EGFR) signaling in AEC regulated key features of allergic airway disease. However, it is unclear what mediators are regulated by EGFR signaling in AEC, although the production of the pro-inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) is EGFR-dependent in keratinocytes. </p> </div><div class="section"> <a class="named-anchor" id="S2"> <!-- named anchor --> </a> <h5 class="section-title" id="d8965602e161">Objectives</h5> <p id="P2">To determine if EGFR signaling regulates GM-CSF production by human AEC downstream of the clinically relevant mediators house dust mite (HDM) and interleukin (IL)-17A and in a mouse model of established allergic asthma. </p> </div><div class="section"> <a class="named-anchor" id="S3"> <!-- named anchor --> </a> <h5 class="section-title" id="d8965602e166">Methods</h5> <p id="P3">EGFR inhibitors were used to determine whether EGFR signaling regulates GM-CSF production by cultured human AEC in response to HDM and IL-17A. The roles of <b>EGFR ligands</b>, p38 mitogen activated protein kinase (MAPK), and tumor necrosis factor alpha (TNFα) converting enzyme (TACE) were also assessed. To determine if EGFR regulates GM-CSF as well as key asthma characteristics in vivo, mice were chronically exposed to HDM to establish allergic airway disease and then treated with the EGFR inhibitor Erlotinib. </p> </div><div class="section"> <a class="named-anchor" id="S4"> <!-- named anchor --> </a> <h5 class="section-title" id="d8965602e174">Results</h5> <p id="P4">EGFR inhibition reduced HDM and IL-17A induced GM-CSF production in a dose-dependent manner in cultured human AEC. GM-CSF production also required <b>amphiregulin</b>, p38 MAPK signaling, and <b>protease/</b>TACE activity. In mice with established allergic airway disease, EGFR inhibition reduced levels of GM-CSF and TNFα, as well as airway hyperreactivity, cellular inflammation, smooth muscle thickening, and goblet cell metaplasia without changes in IgE and Th1, Th2, and Th17 cytokines. </p> </div><div class="section"> <a class="named-anchor" id="S5"> <!-- named anchor --> </a> <h5 class="section-title" id="d8965602e185">Conclusions and Clinical Relevance</h5> <p id="P5">Results link HDM, IL-17A, <b>amphiregulin</b>, EGFR and GM-CSF in a mechanistic pathway in AEC, and demonstrate that EGFR regulates GM-CSF production and the severity of established disease in a clinically relevant asthma model. These results identify the EGFR→GM-CSF axis as a target for therapeutic development. </p> </div>

          Related collections

          Most cited references50

          • Record: found
          • Abstract: not found
          • Article: not found

          Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Global strategy for asthma management and prevention: GINA executive summary.

            Asthma is a serious health problem throughout the world. During the past two decades, many scientific advances have improved our understanding of asthma and ability to manage and control it effectively. However, recommendations for asthma care need to be adapted to local conditions, resources and services. Since it was formed in 1993, the Global Initiative for Asthma, a network of individuals, organisations and public health officials, has played a leading role in disseminating information about the care of patients with asthma based on a process of continuous review of published scientific investigations. A comprehensive workshop report entitled "A Global Strategy for Asthma Management and Prevention", first published in 1995, has been widely adopted, translated and reproduced, and forms the basis for many national guidelines. The 2006 report contains important new themes. First, it asserts that "it is reasonable to expect that in most patients with asthma, control of the disease can and should be achieved and maintained," and recommends a change in approach to asthma management, with asthma control, rather than asthma severity, being the focus of treatment decisions. The importance of the patient-care giver partnership and guided self-management, along with setting goals for treatment, are also emphasised.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Evidence of a role of tumor necrosis factor alpha in refractory asthma.

              The development of tumor necrosis factor alpha (TNF-alpha) antagonists has made it feasible to investigate the role of this cytokine in refractory asthma. We measured markers of TNF-alpha activity on peripheral-blood monocytes in 10 patients with refractory asthma, 10 patients with mild-to-moderate asthma, and 10 control subjects. We also investigated the effects of treatment with the soluble TNF-alpha receptor etanercept (25 mg twice weekly) in the patients with refractory asthma in a placebo-controlled, double-blind, crossover pilot study. As compared with patients with mild-to-moderate asthma and controls, patients with refractory asthma had increased expression of membrane-bound TNF-alpha, TNF-alpha receptor 1, and TNF-alpha-converting enzyme by peripheral-blood monocytes. In the clinical trial, as compared with placebo, 10 weeks of treatment with etanercept was associated with a significant increase in the concentration of methacholine required to provoke a 20 percent decrease in the forced expiratory volume in one second (FEV1) (mean difference in doubling concentration changes between etanercept and placebo, 3.5; 95 percent confidence interval, 0.07 to 7.0; P=0.05), an improvement in the asthma-related quality-of-life score (by 0.85 point; 95 percent confidence interval, 0.16 to 1.54 on a 7-point scale; P=0.02), and a 0.32-liter increase in post-bronchodilator FEV1 (95 percent confidence interval, 0.08 to 0.55; P=0.01). Patients with refractory asthma have evidence of up-regulation of the TNF-alpha axis. (ClinicalTrials.gov number, NCT00276029.). Copyright 2006 Massachusetts Medical Society.
                Bookmark

                Author and article information

                Journal
                Clinical & Experimental Allergy
                Clin Exp Allergy
                Wiley
                09547894
                February 2016
                February 2016
                January 28 2016
                : 46
                : 2
                : 317-328
                Affiliations
                [1 ]Division of Pulmonary Biology; Perinatal Institute; Cincinnati Children's Hospital Medical Center; Cincinnati OH USA
                [2 ]Department of Pediatrics; University of Cincinnati College of Medicine; Cincinnati OH USA
                [3 ]Translational Pulmonary Science Center; Perinatal Institute; Cincinnati Children's Hospital Medical Center; Cincinnati OH USA
                [4 ]Division of Pulmonary Medicine; Perinatal Institute; Cincinnati Children's Hospital Medical Center; Cincinnati OH USA
                [5 ]Division of Pulmonary, Critical Care and Sleep Medicine; University of Cincinnati College of Medicine; Cincinnati OH USA
                Article
                10.1111/cea.12612
                4732899
                26263242
                09b8de4d-2ba9-4760-9501-d37761058388
                © 2016

                http://doi.wiley.com/10.1002/tdm_license_1.1

                History

                Comments

                Comment on this article